 Sarepta Therapeutics Inc NASDAQ: SRPT is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on its own as it prepares for a pivotal readout in mid-year. According to Lysogene, Sarepta returned the global commercial rights for LYS-SAF302 after unsuccessful discussions for transferring back to Lysogene the responsibility for the global commercial supply of LYS-SAF302. 